ArticleCardiology research and practice2011
Metabolic syndrome, chronic kidney disease, and cardiovascular disease: a dynamic and life-threatening triad.
Article in Cardiology research and practice, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Integrating inflammation, insulin resistance, and visceral adiposity: the C-reactive protein-triglyceride-glucose-Chinese visceral adiposity (CTI-CVAI) index is associated with cardiovascular disease risk across CKM stages 0-3 in a nationwide prospective cohort.Cardiovascular diabetology · 2026Article
- Multimorbidity among indigenous tribal communities in Kerala, India: a cross-sectional study (2022-2024).The Lancet regional health. Southeast Asia · 2026Article
- Longitudinal changes in estimated glucose disposal rate and risk of cardiovascular disease among adults with cardiovascular-kidney-metabolic syndrome stages 0-3: a nationwide prospective cohort study.European journal of medical research · 2025Article
- First-time diagnosis and referral practices for individuals with CKD by primary care physicians: a study of electronic medical records across multiple clinics in Japan.Clinical and experimental nephrology · 2025Observational
- Pathophysiology and emerging biomarkers of cardiovascular-renal-hepato-metabolic syndrome.Frontiers in cardiovascular medicine · 2025Review
- Metabolic syndrome as a risk factor for the development of kidney dysfunction: a meta-analysis of observational cohort studies.Journal of diabetes and metabolic disorders · 2024Review
- Molecular Interaction of Soluble Klotho with FGF23 in the Pathobiology of Aortic Valve Lesions Induced by Chronic Kidney Disease.International journal of biological sciences · 2024Article
- Impact of time-restricted feeding on kidney injury in male rats with experimental metabolic syndrome.Experimental physiology · 2023Article
- Activation of angiotensin-converting enzyme 2 ameliorates metabolic syndrome-induced renal damage in rats by renal TLR4 and nuclear transcription factor κB downregulation.Frontiers in medicine · 2022Article
- Effect of Dapagliflozin and Magnesium Supplementation on Renal Magnesium Handling and Magnesium Homeostasis in Metabolic Syndrome.Nutrients · 2021Article
- Chronic Kidney Disease as a Systemic Inflammatory Syndrome: Update on Mechanisms Involved and Potential Treatment.Life (Basel, Switzerland) · 2021Review
- Bidirectional and Temporal Association Between Hypertension and Microalbuminuria: A Longitudinal Study in Chinese Adults.Journal of the American Heart Association · 2018Article
- Kidney Androgen-Regulated Protein (KAP) Transgenic Mice Are Protected Against High-Fat Diet Induced Metabolic Syndrome.Scientific reports · 2017Article
- Metabolic syndrome in peritoneal dialysis patients: choice of diagnostic criteria and prognostic implications.Clinical journal of the American Society of Nephrology : CJASN · 2014Article
- Metabolic syndrome, C-reactive protein and microalbuminuria in a rural Chinese population: a cross-sectional study.BMC nephrology · 2013Article
- Interaction Effects of the Leu162Val PPAR α and Pro12Ala PPAR γ 2 Gene Variants with Renal Function in Metabolic Syndrome Population.PPAR research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The metabolic syndrome (MS) and chronic kidney disease (CKD) have both become global public health problems, with increasing social and economic impact due to their high prevalence and remarkable impact on morbidity and mortality. The causality between MS and CKD, and its clinical implications, still does remain not completely understood. Moreover, prophylactic and therapeutic interventions do need to be properly investigated in this field. Herein, we critically review the existing clinical evidence that associates MS with renal disease and cardiovascular disease, as well as the associated pathophysiologic mechanisms and actual treatment options.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.